
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Industries is projected to experience notable sales growth across its product portfolio, with forecasts indicating Ajovy sales reaching $785 million and Uzedy sales reaching $278 million by 2026, showing year-over-year increases of 17% and 45% respectively. The company's robust performance is supported by significant gains in raw volume, pricing improvements, and a strategic shift towards higher-value products, which is expected to enhance EBITDA margins. Furthermore, the potential for Austedo to achieve peak sales exceeding $3 billion, paired with ongoing cost-saving initiatives targeting $700 million by 2027, underscores a favorable outlook for Teva's future cash flows.
Bears say
Teva Pharmaceutical Industries is projected to experience a declining trend in revenues, with expectations of a year-over-year decrease in 4Q26 driven by pricing pressures and inventory patterns. Additionally, despite a positive outlook for Austedo in 2026, forecasts indicate a negative revenue trajectory in 2027, signaling potential challenges in sustaining growth. Coupled with missed revenue expectations in the generics segment and ongoing risks related to regulatory uncertainty, litigation, and pipeline execution, the company's financial stability appears under threat.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares